Internal Medicine, Rheumatology · El Paso, TX
NPI
1316916125
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
5
Medicare group memberships
Hospitals
4
Hospital affiliations
2600 N Oregon St
El Paso, TX, 79902
Phone (915) 317-1660
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.6M
332,948 services
Medicare patients, 2024
702
Average age 71
Drug cost, 2024
$4.3M
3,203 prescriptions
Company payments, 2025
$412K
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sanjay Chabra was code J3262 (injection, tocilizumab, 1 mg), 195,357 times for 38 patients. In total Sanjay Chabra billed 332,948 services in 53 codes, and Medicare paid $4.6M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-10-06.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3262 Injection, tocilizumab, 1 mg | Office | 195,357 | 38 | $4.69 | $915K |
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 60,000 | 17 | $3.57 | $214K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 28,700 | 41 | $9.07 | $260K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 8,200 | 13 | $33.89 | $278K |
| J0897 Injection, denosumab, 1 mg | Office | 3,420 | 34 | $20.40 | $70K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 2,051 | 22 | $0.09 | $183 |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 1,628 | 60 | $0.22 | $356 |
| 99214 Office E&M - Established | Office | 1,077 | 593 | $75.94 | $82K |
| 96413 Chemotherapy Administration | Office | 858 | 122 | $95.24 | $82K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 540 | 405 | $12.43 | $6,713 |
| 96401 Chemotherapy Administration | Office | 397 | 51 | $52.72 | $21K |
| 99215 Office E&M - Established | Office | 300 | 219 | $119.01 | $36K |
| J1885 Injection, ketorolac tromethamine, per 15 mg | Office | 253 | 37 | $0.50 | $126 |
| 96375 Injection Administration | Office | 194 | 27 | $11.36 | $2,205 |
| 96415 Chemotherapy Administration | Office | 183 | 25 | $20.33 | $3,721 |
By year: 2022 $3.5M for 255,476 services; 2023 $4.5M for 289,768 services; 2024 $4.6M for 332,948 services.
Medicare prescription drug claims, 2024
In 2024, the drug Sanjay Chabra prescribed most often to Medicare patients was Prednisone, with 423 prescriptions and refills. In total Sanjay Chabra wrote 3,203 Medicare prescriptions that cost $4.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 423 | 1,112 | 168 | $2,824 |
| Leflunomide Generic | 280 | 808 | 109 | $17K |
| Methylprednisolone Generic | 229 | 273 | 141 | $2,329 |
| Hydroxychloroquine Sulfate Generic | 223 | 649 | 93 | $12K |
| Methotrexate Methotrexate Sodium | 177 | 495 | 69 | $3,945 |
| Duloxetine Hcl Generic | 153 | 424 | 58 | $4,503 |
| Celecoxib Generic | 150 | 417 | 70 | $5,721 |
| Mycophenolate Mofetil Generic | 133 | 342 | 46 | $13K |
| Gabapentin Generic | 108 | 269 | 48 | $1,467 |
| Baclofen Generic | 90 | 222 | 49 | $1,026 |
| Folic Acid Generic | 88 | 268 | 31 | $862 |
| Meloxicam Generic | 79 | 207 | 43 | $530 |
| Azathioprine Generic | 77 | 227 | 33 | $3,730 |
| Cyltezo(Cf) Pen Adalimumab-Adbm | 67 | 67 | 11 | $487K |
| Sulfasalazine Generic | 61 | 163 | 31 | $1,298 |
Brand drugs: 512 claims; generic drugs: 2,677 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sanjay Chabra $412K ($412K in general payments such as food, travel and fees) from 20 companies. The largest payer was Amgen Inc. with $103K.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 127 | $103K |
| AstraZeneca Pharmaceuticals LP AZN | 64 | $64K |
| Abbvie Inc. ABBV | 58 | $49K |
| UCB, Inc. UCB.BR | 59 | $47K |
| Genzyme Corporation SNY | 32 | $31K |
| ANI Pharmaceuticals, Inc. ANIP | 39 | $29K |
| Mallinckrodt Hospital Products Inc. | 29 | $25K |
| GlaxoSmithKline, LLC. GSK | 22 | $18K |
| Aurinia Pharma U.S., Inc. AUPH | 26 | $17K |
| Lilly USA, LLC LLY | 12 | $10K |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.